2025-03-31-accounts

CIO

Trustees report and Financial Statements

for the year

1 April 2024 to 31 March 2025

Registered Charity 1198883

1

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

EOS Network – Eosinophilic Diseases Charity

Contents	Page
Welcome From CEO	3
Report of the Trustees	4 - 21
Statement of Financial Activities	22
Balance Sheet	23
Notes to the Financial Statements	24 - 26
Independent Examiner’s report	27

2

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

Welcome from CEO and Founder

This year has been an exciting year of evolution. Having been involved in Eosinophilic advocacy for over 2 decades it felt my journey had made a full circle back to 2010 when much of the understanding of these conditions was still hypotheses. At that time people living with the symptoms knowing they went way beyond the gut but with little or no evidence causing disbelief and lack of recognition.

Fast forward to 2024 with our awareness campaigns, co-authoring of guidelines for Eosinophilic Oesophagitis EoE and advocacy for access to the first approved treatment, recognition of EoE was no longer in question and prevalence doubled to 1 in 700. However, the challenge of 8 years to diagnosis remained raising the question: How do we get people to realise they should seek help earlier for this this silent progressive condition?

Meanwhile our global research partners focus could now begin to move forward into the lesser-known complexities of Eosinophilic gastrointestinal diseases beyond the Oesophagus, and we were delighted to be part of developing the first comprehensive global paediatric to adult medical guideline essential for diagnosis and care.

Our patient representative role within multiple medical institutes and with corporate partners ensured we were able to highlight the latest research as it became available. Research from the revolutionary biological medicines brought new insights. Positive trial results taught us the connection we once hypothesised about was in fact true and Eosinophilic gastrointestinal disease were on the same pathway as Type 2 inflammatory conditions in skin, lung, nasal and other organs. Negative trial data taught us that the Eosinophil is not the only cell causing the problem.

This was a pivotal moment for our community as it confirmed people with Eosinophilic diseases need to be considered in a much more holistic way; understanding now that type 2 inflammatory conditions such as asthma, eczema, rhinitis, allergy, Eosinophilic Oesophagitis and functional gut conditions like IBS may not only coexist but also be associated eosinophilic diseases (EADs).

Here is the circle as all that time ago in 2010 when it was just hypothesis a medical expert and I sat in a hospital canteen and together wrote a leaflet on Eosinophilic associated diseases that today could be backed with robust medical evidence.

With empowering our community to self-advocate and manage their care needs being at the heart of everything we do this new evidence is key to developing our 2025 campaign: recognising and reporting the signs and symptoms of the gut and beyond which are the clues to seeking earlier diagnosis and appropriate cohesive care.

Our work continues to increase awareness, advocate for earlier diagnosis, joined up patient centred care and access to personalised medicines all essential for people to lead healthier better-quality lives

Thank you to our community of lived experience, EOS medical professional network, fundraiser donors and partners experts working together to improve people’s lives. We cannot wait to see what is achieved in the coming year.

Amanda Cordell

CEO and Founder Amanda Cordell

3

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

Who we are

EOS Network is the only UK charity focused on improving the lives of the 1 in 700 people and their families affected by lifelong Type 2 Inflammatory Eosinophilic Associated Diseases. We support a growing community of people affected and have established a global healthcare professional network, together we strive to improve awareness, and knowledge to reduce health inequalities for these complex conditions that impact the sufferer and their families.

Our vision

A world where lives are no longer inhibited and controlled by Eosinophilic-Associated Diseases.

Our mission

Is to ensure that every person with an Eosinophilic-Associated Disease receives a prompt, accurate diagnosis, cohesive medical care, and support to live with their condition.

Our Values

We aspire to be well-informed collaborative agents of change, dedicated to improving our Community’s future.

We are inclusive, compassionate and devoted to ensuring that everyone should feel respected, empowered and supported in health as a whole person.

Our behaviours

We are driven, open with everyone, and focused on getting results for our community.

We are led by our community’s voice in all aspects of our charity’s work.

4

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

EOS Network – Eosinophilic Diseases Charity

Trustees’ report

For the year ended 31 March 2025

The Trustees present their annual report and financial statements of EOS Network - Eosinophilic Diseases Charity for the period ended 31 March 2025

REFERENCE AND ADMINISTRATIVE INFORMATION

Charity name: EOS Network – Eosinophilic Diseases Charity

Charity Registration Number: 1198883

Trustees:

Amanda Cordell Bernard Michael McGrath Mark Nicholas Boulding Philippa Rosemary Dennitts David Cordell Lesley Perkin

Bankers: NatWest Bank Plc

Administrative address: Alpenrose Weeley Road Great Bentley Colchester CO7 8PD

Independent Examiner:

Simon Robinson SAS Accounting Services Ltd The Colchester Centre Hawkins Road Colchester CO2 8JX

5

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

EOS Network – Eosinophilic Diseases Charity

Trustees’ report (continued)

The Trustees present their Trustees’ report and financial statements in accordance with the Charities Act 2011 and the Charity SORP 2005.

1. Structure, governance, and management

• The governing document

The Charity EOS Network was constituted as a Charitable Incorporated Organisation (CIO) on 5[th] May 2022. Evolving from an unincorporated charity registered status since 2012 under registration number 1143267 which was initially started in 2004 as a yahoo patient support group.

30[th] March 2023 The governing document and name of the Charity was updated to EOS Network – Eosinophilic Diseases Charity for the benefit of increasing public awareness.

Organisational structure and management

EOS Network is governed by its Trustee Board which is responsible for setting the strategic direction of the organisation and the policy of the charity. Trustees meet as a minimum four times per year and review operational, financial and strategic progress at these meetings.

• Trustees

The Trustees holding office during the period and up to the date of this report (unless otherwise stated) are:

Amanda Cordell Bernard Michael McGrath Mark Nicholas Boulding Philippa Rosemary Dennitts David Cordell Lesley Perkin

• Recruitment and appointment of Trustees

The trustees are appointed in accordance with the governing document. Future trustees may be appointed by a resolution of the trustees passed at a meeting of the of the trustees.

• Trustee induction and training

Trustees are selected for their expertise that is relevant to the charity, so that a wide knowledge base can be brought to bear on fundraising, finance and administration. Each year the Trustees review their collective ability to fulfil the charity’s objectives.

• Statement of trustees’ responsibilities

Law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the Charity’s financial activities during the year and of its financial position at the end of the year. In preparing the financial statements giving a true and fair view, the trustees should follow best practice and:

• i. Select suitable accounting policies and then apply them consistently;

• ii. Make judgements and estimates that are reasonable and prudent;

• iii. State whether applicable accounting standards have been followed, subject to any material departures and explained in the financial statements; and

6

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

• iv. Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping accounting records which disclose with reasonable accuracy the financial position of the charity, and which enable them to ensure that the financial statements comply with the Charities Act. They are also responsible for safeguarding the assets of the charity and hence, for taking reasonable steps for the prevention and detection of fraud and other irregularities. They are required to apply the funds of the charity with complete fairness to meet the objects of the charity.

• Investment powers and policy

The governing document grants unrestricted powers of investment to the trustees.

• Risk management

The Trustees consider the charity is exposed to little risk, but this position is periodically reviewed and documented.

2. Objectives and activities

The objects of the CIO are:

The relief of sickness and the preservation of health among people with Eosinophilic-Associated Diseases, and by extension their families and carers, in particular, but not exclusively by:

(a) Advancing the education of the general public and the medical profession in all areas relating to EosinophilicAssociated Diseases;

(b) Providing relief to and promoting the good physical and mental health of persons diagnosed with EosinophilicAssociated Diseases, and by extension their families and carers through a community hub and the provision of resources, advice, guidance and events; and

(c) Funding, sharing and cooperating with national and international organisations to support medical research into the causes, treatment and cure of Eosinophilic-Associated Diseases.

3. Public benefit statement

EOS Network operates for public benefit. The trustees confirm that they complied with the duty in Section 17 of the Charities Act 2011 to have due regard to the general guidance on public benefit, ‘Charites and Public Benefit’.

7

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

4. Achievement and performance during the period 1[st] April 2024 to 31st March 2025

The EOS Network CIO was incorporated on 10[th] May 2022, as a successor organisation of registered charity 1143267 unincorporated association of the same name.

A year of growth in community, patients voice, reach and structure.

We measured our impact with our Feb 2025 Activities and Feedback Survey* 240 community and professional members participated.

*95% would recommend our services.

*40% survey participants chose to comment on how our services had made a difference – these comments and further statistics are shared throughout our annual report.

‘Key to fighting this condition is awareness and education - information is power - and your network provides that via multiple avenues.’ *

We published 98 new webpages and gained over 55K new website visitors

• We shared 625 social media posts reaching 180K impressions

• Our social followers reached over 6k a growth of 14%

• Partnerships amplified our EAD awareness to reach millions of people.

8

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

Educate, Connect, Empower and Advocate

We provided quality information and practical support for people with Eosinophilic Associated Diseases, their families and carers through our community hub, resources and events.

Our registered patient carer community grew to over 1.1k members

We surveyed our patient/carer community to understand the value we bring. They said that in their experience, we had empowered them with knowledge (77%), made them feel supported and less isolated (56%), connected them with the EOS community (46%), and gave them confidence to ask their doctor questions (44%) .

‘Knowledge gained through webinars, speaking to Amanda, the website, news updates, all this has helped with understanding of the disease and empowered us to seek the best treatment and how to live life to the full as possible whilst living with Eosinophilic disease’ *

Support

We continued to provide life changing one-to-one telephone or email support to new and existing members.

Inform

76% of survey respondents reported finding our newsletters helpful. With our email campaigns achieving an average open rate of 62% - feedback told us how this accessible information has made a difference in people’s lives. Key information included seasonal dietary resources, education videos on understanding clinical trials and the latest research news in lay term - read friendly formats. Work began on a series of 6 empowering webinars and community chats due 2025 supported by the National Lottery Community Fund.

Improving Diagnosis

“EOS Network provided me with the invaluable information I needed to challenge my GP’s inaccurate diagnosis of my symptoms. Like many other EOE sufferers, my concerns about my symptoms were dismissed as acid reflux. Without EOS I would have not had the confidence to challenge my GP and fight for better healthcare. Knowing that there is a community of fellow EOE sufferers that I can connect with has been a great comfort to me.” *

‘Helpful to read of others specific experiences with EOE. I have had EOE symptoms for at least 16yrs. Diagnosed, 5yrs ago. I am a retired Med Lab Tech and I had never heard of it prior to my diagnoses.’ *

9

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

Tools and Resources

We published six real-life community ‘Eosinophilic Voices’ personal journeys and provided downloadable tools, including adding a new series on clinical trial processes and terminology to our video educational resources which have received 12 500 views .

Photo: Community members who participated in Eosinophilic Voices project

‘We want to say thank you for all the information and Video Presentations on your website. My adult son has just been diagnosed with EoE, he has a stricture & will commence treatment soon. Your pages and videos are extremely helpful, informative & Supportive, and despite something of a 'scary' diagnosis they are practical & well balanced. We now feel more empowered for when we go back to the specialist next week.’

We held online community meetings for people to meet others facing the same challenges.

What Our Community Said About Our Online Meet Ups

‘In the Community Chat events I've benefited from hearing and sharing experiences with other EOS patients and experts, which I would never have done otherwise. That's immensely helpful not just for reducing any feeling of condition 'isolation' but also for picking up genuine advice on managing the condition’ *

‘I found the friendly and accessible web chats really helpful after my diagnosis as it was all new to me. Web based links have also helped me to further my knowledge.’ *

‘Having people to speak to with similar issues is priceless’ *

10

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

A Global Reach In Healthcare and Research

We exhibited and attended numerous medical congresses, expanding our presence and relationships with key institutions far beyond gastro-enterology.

At the European Society of Gastroenterology and Hepatology congress ESPGHAN 2024 we distributed over 1000 leaflets and met with new and existing network members.

We were delighted to collaborate with attendees and speakers discussing EADs and multisystem allergic diseases at the 2024 conference of the British Society of Allergy and Clinical Immunology (BSACI).

Our CEO networked with leading researchers and clinicians at United European Gastroenterology UEG2024, and EUREOS annual meeting building new collaborative relations to advance our mission .

11

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

Work began on a global position paper for Eosinophilic Oesophagitis EOS Growing Professional Network

A further 108 Multidisciplinary Healthcare Professionals (HCPs) became members of EOS Network, and a total of 554 are now receiving regular news and research updates, accessing practical support tools for their clinics, and connecting with each other.

Our HCP newsletters have all achieved opening rates in excess of 50%, which by industry standards is exceptional.

We surveyed our registered HCP community to understand what value EOS Network has brought to them*.

• 68% of respondents said we provide useful tools and services to support their patients

• 45% said we inform them of global research and guidelines

• 42% said that we have expanded their knowledge

• 35% said we have connected them with other healthcare professionals.

Finding a healthcare professional with the necessary expertise can be very difficult for patients, during this period an additional 25 agreed to be featured on our website ‘Find a doctor’ map.

“I have received advice on finding specialists in my area which has been invaluable.” *

We supported our professional members when peer educating colleagues to improve awareness and implementation of guidelines and

were delighted to be invited to exhibit at Broomfield Hospital round table where Gastroenterologist - Dr Rakshit spoke about ‘The importance of the district general hospital’s role in earlier intervention for EoE in order to avoid fibrous damage caused by delayed diagnosis.’

12

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

Representing The Patients Voice

We were invited to join the public affairs committee of European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) and the patient organisations committee of The European Academy of Allergy and Clinical Immunology (EAACI). These relationships enabled us to become the unifying patient voice in EADs across disciplines, institutions, at a national and European level.

We continued to represent our community’s voice within British Society for Gastroenterology Hepatology and Nutrition BSPGHAN and the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). We helped develop a process for ESPGHAN to appraise and endorse patient support materials from PAGs. We began development of a series of webinars for Patients Carers and HCPs on the interconnected symptomatology and pathology of EADs, looking beyond their own specialisms, these are due to be delivered in 2025.

We advocated to our industry partner Sanofi to co-develop a new educational resource ‘Could it be EoE?’ This collaboration brought together our patient group colleagues from around the globe to highlight the holistic signs and symptoms experienced by our communities. This tool will be used to raise awareness of the silent but progressive clues among the public and all clinical services to reduce diagnosis times and improve cohesive care.

This resource was developed both as a poster and leaflet and made available online and in hard copy, we plan to distribute throughout 2025/26.

13

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

Supporting Research For Better Diagnostic Tools

We convened focus groups, for example on the QuBIE capsule sponge clinical trial (picture right) which could make EoE diagnosis much less invasive, to give patients a voice in their treatment. We represented the patients experience in the SWALLOW feasibility study with Catherine Sykes.

We featured researchers such as leading expert Prof Marc

Rothenberg (picture below), Molly Shook and in our podcasts, video and website discussing the future of diagnostics and treatments for Eosinophilic Associated Diseases.

Supporting Research for Holistic EAD Care

As per our community’s request, we expanded our global research news to cover allergic: skin, lung, nasal and gut, type 2 inflammatory conditions. Inviting Willam Fong and members of our network to present their studies.

14

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

Bringing the patients voice to medical research publications and care guidelines

We are proud to have co-authored 5 publications and abstracts highlighting and evidencing the challenges faced by our community:

1. Segmental overlap is common in eosinophilic gastrointestinal diseases and impacts clinical presentation and treatment.

Ketchem CJ, Jensen ET, Dai X, Anderson C, Kodroff E, Strobel MJ, Zicarelli A, Gray S, Cordell A, Hiremath G, Dellon ES. Dis Esophagus. 2025 Jan 7;38(1):doaf011. doi: 10.1093/dote/doaf011. PMID: 40036388; PMCID: PMC12187587.

2. Swallowed topical steroid therapy for eosinophilic oesophagitis in children: practical, evidencebased guidance by the BSPGHAN Eosinophilic Oesophagitis Working Group.

Chan J, Flynn DM, Gordon M, Parmar R, Moolenschot K, Jackman L, Gaynor E, Epstein J, Cordell A, Kannappan H, Furman M, Thompson J, Gasparetto M, Auth MKH . BMJ Paediatr Open. 2024 May 23;8(1):e002467. doi: 10.1136/bmjpo-2023002467. PMID: 38782481; PMCID: PMC11116858.

Marcus Auth (above) presenting at European Society for Paediatric Gastroenterology Hepatology and Nutrition

3. Baseline survey on the management of paediatric eosinophilic oesophagitis in the UK and Ireland from the BSPGHAN EoE working group

Regas C, May G, Chan J, et al OC10 Frontline Gastroenterology 2024;15:A8. DOI: 10.1136/flgastro-2024bspghan.10

4. Health professionals survey of transition service in eosinophilic oesophagitis in UK – a BSPGHAN EoE Working group initiative

Parmar RS, Moolenschot K, Cordell A , et al OC11 Frontline Gastroenterology 2024; 15: A8-A9. DOI: 10.1136/flgastro-2024-bspghan.11

5. Frequent report of vitamin deficiencies and use of supplements and complementary/alternative treatment approaches in patients with eosinophilic gastrointestinal diseases.

Cameron BA, Jensen ET, Dai X, Anderson C, Kodroff E, Strobel MJ, Zicarelli A, Gray S, Cordell A, Hiremath G, Dellon ES. Ther Adv Rare Dis. 2025 Mar 14;6:26330040251326928. doi: 10.1177/26330040251326928. PMID: 40094151; PMCID: PMC11907540.

We continued to provide patient perspective review comments for the latest guidelines in Eosinophilic Gastrointestinal Diseases including the development of the first paediatric – adult Non EoE Lower EGIDs international guideline.

15

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

Growing A Sustainable Organisation

Our team

As per our strategic plan we have grown our team to include a part time dedicated fundraising officer.

New and existing volunteers played a vital role in our work providing lived experience, personal work or life skills and expert medical or scientific advice. We identified to maximise this opportunity going forward it is essential that more core staff are employed to support and sustain a positive voluntary experience.

Our Systems

We further developed our community relations management CRM to optimise our communications, support and community engagement. We trialled several workflow programmes to optimise our small but mighty team’s time and efficacy. We successfully completed our annual external I.T, GDPR and security review.

Fundraising

Having our new fundraiser Karen in post has enabled us to develop additional fundraising tools and challenge opportunities including holding a dedicated fundraising workshop.

We thank our fundraisers: London Marathon runners Katie and Carla, Serpentine Swimmer Florence, The Junior Great North Run participant William and our generous community of donors who together raised a total of £10,434.

Development of our CRM will enable us to improve our donor journey ensuring we can inform people of the difference their generosity has made.

As per our fundraising strategy we submitted 14 fundraising applications to trusts and foundations and were grateful to have successfully received awards in this period from The National Lottery Community Fund and Fowler Smith and Jones (FSJ Charities). Further applications were submitted to employ a part time administrator and community projects officer to support our team in line with the exponential growth in demand for services and complexity of our mission we await their outcome.

Corporate partners and pro bono services or gifts in kind relations continued to play an essential role in our funding we thank Astra Zeneca, Sanofi - Regeneron, Bristol Myers Squibb, Dr Falk Pharma, Google, Microsoft and Pillsbury Winthrop Shaw Pittman LLP for their support in achieving our mission.

16

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

Listening to our Community

The needs of the people affected by Eosinophilic associated diseases are at the heart of our mission. We connect and learn from our communities’ voices through many channels including:

• Website forms and contact enquiries

• Phone and email 1 to 1 support services

• Online events

• In person meetings

• Social media platforms

• In event polls and after event feedback surveys

• Focus groups and surveys

The valuable insights gained from these sources alongside our Feb 2025 impact and feedback survey will help shape our future activities.

17

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

6. Financial review

i. Results for the year ending 31 March 2025

Income for the year was £204,479 (2024: £205,688) which includes £70,245 (2024: £127,921) in respect of donated services an equivalent amount is included resources expended. Expenditure for the year was £205,473 (2024: £238,038) resulting in a deficit of £994 (2024: £32,350) and with reserves of £43,666 brought forward from 1[st] April 2024 reserves at 31[st] March 2025 were £42,673

We are thankful for the continued dedicated support of volunteers, community fundraisers and the generosity of our donors and corporate sponsors without whom our achievements would not have been possible.

Grants and Donations were gratefully received from the following supporters: The National Lottery, Google, Microsoft, Pilsbury Winthrop Shaw and Pittman LLP, Astra Zeneca, Regeneron – Sanofi, Bristol Myers Squibb, Dr Falk Pharma UK and FSJ.

i. Reserves

The Trustees’ policy on reserves requires that reserves shall be used for the following purposes:

to provide fixed and working capital; to provide for future contingencies; and to provide a base for future development to deliver the charity’s strategic objectives.

The charity has financial reserves that can be a combination of restricted and unrestricted reserves. Restricted reserves are funds that have been given for a specific charitable purpose.

The Trustees consider that the available reserves (i.e. liquid and readily realisable assets, excluding restricted funds represented in these assets) should be maintained in a range between three and six months of operational expenditure.

The Trustees also recognise that owing to the need for resources to be used to finance planned expansion, there may be periods when reserves cannot be maintained within these limits, however sufficient reserves shall be maintained to cover known commitments. The reserve levels required under the reserves policy will be kept under review.

18

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

7. Future Plans for 2025-26

During 2023-24, we refreshed the strategy which had been in place since 2021. Much has changed during this time, as EoE has become better recognised, and research has highlighted the interconnectivity of many eosinophilic associated diseases (EADs), within and beyond the gastrointestinal tract. Our new strategy will address the following key issues:

1. Emerging scientific evidence in EADs is yet to be translated into robust clinical evidence

There is growing recognition in specialist/research centres, of the complexity of eosinophilic-associated disease models. This needs to be corroborated in robust clinical evidence, to drive changes in routine practice.

1. Multi-disciplinary care has not yet caught up with advances in scientific understanding of EADs

Our understanding of eosinophilic-associated diseases is improving. We now know that some patients experience multiple EADs affecting different body systems, while many others are affected by concomitant diseases (often atopic), which can be important flags for prompt diagnosis and also require treatment. However, this raises the bar of effective ongoing multi-disciplinary leadership and collaboration in traditional specialtybased healthcare provider structures.

1. Our patient-carer community needs far more than just information about their chronic disease

To live their best lives in existing healthcare systems, patients and carers need to be able to self-advocate. This requires skills and support structures, as well as information about their EADs and the concomitant conditions which should trigger appropriate investigations by HCPs.

1. Our recent growth in reach and capacity necessitates increased sustainable funding

To reach more people and drive greater change, we have invested in paid staff and need to be able to maintain that commitment. Furthermore, to make full use of the opportunities we have unlocked (especially with our CRM system), we need to increase our funding as well as ensuring it is sustainable.

We have set four new strategic goals to address these issues, which we will work towards in 2024-26:

Goal 1: Improve real world EAD impact evidence

We will gather more data from patients and HCPs, on the experience, diagnosis and treatment of EADs and concomitant diseases, with a gastro-intestinal component, in a structured way and on a global scale. Developing robust multiple systemic diseases evidence, to improve patient outcomes through holistic understanding, research, treatments and practices.

2025/26 priority activities for Goal 1

1. Continue to maintain and develop EOS Network community registration CRM data and participate in collaborative projects

2. Develop patient registry project plan and secure funding

3. Recruit a steering committee to map the registry’s key aims, scope, content, control and management

4. Select a suitable provider, to build the patient registry

5. Form a robust plan to secure ongoing patient registry funding

19

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

Goal 2: Build Bridges

We will foster models of multi-disciplinary collaboration between specialties and across paediatric and adult services, to improve diagnosis and management of EADs which have a gastro-intestinal component, and concomitant diseases.

2025/26 priority activities for Goal 2

1. Advocate for standardised optimal cohesive care and research within medical bodies and other stakeholders as official EAD patient representation

2. Deliver a pilot project using electronic health care records to demonstrate the massive underdiagnosis of EoE in the UK and develop tools to transform it

3. Expand our website content on EADs and concomitant diseases

4. Run a webinar series for HCPs on the interconnected symptomatology and pathology of EADs, looking beyond their own specialisms

5. Plan a conference on leading/achieving system change for EADs management in both adult and paediatric services

Goal 3: Empower patients & carers

We will empower patients and carers living with EADs which have a gastro-intestinal component to get what they need from their healthcare providers.

2025/26 priority activities for Goal 3

1. Provide educational information for EAD patients/carers on their disease and the relevance of any concomitant symptoms, through a leaflet and our website

2. Develop a practical tool to help patients communicate the overall picture of their symptoms to their HCPs

3. Run a patient/carer community event (in person or online) to connect people, deepen their understanding of how to navigate the challenges of their healthcare system, and launch our new resources

4. Focus Eosinophilic Awareness Month on raising awareness amongst patients, carers and HCPs of EADs and concomitant diseases

5. Recruit a paid Community Projects Officer to maximise the reach and impact of these initiatives, and provide increased personalised support to patient/carer Community members

Goal 4: Increase sustainable funding

We will increase and diversify our income and make it more sustainable.

2025/26 priority activities for Goal 4

1. Allocate specific staff resource to increase our level of targeted fundraising activity

2. Diversify our fundraising efforts to include Trusts & Foundations, and Community fundraising

3. Deepen and broaden our engagement with actual/potential pharmaceutical company funders

20

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

1. Seek multi-year funding commitments to enable longer term projects such as our Registry.

Approved by the Trustees on 29/9/25 and signed on their behalf by

Chair of Trustees

Amanda Cordell

Treasurer and Trustee

Bernard McGrath

21

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

EOS Network – Eosinophilic Diseases Charity

Statement of Financial Activities

For the year ended 31 March 2025

22

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

EOS Network – Eosinophilic Diseases Charity

Balance Sheet as at 31 March 2025

These financial statements were approved by the board

and signed on its behalf by Chair of Trustees Amanda Cordell

Treasurer and Trustee Bernard McGrath

Date: 29/9/25 Charity Number 1198883 The notes on pages 24 to 26 form an integral part of these financial statements

23

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

EOS Network – Eosinophilic Diseases Charity

Notes to the financial statements

For the year ended 31 March 2025

Accounting policies

• I. Basis of preparation

The financial statements have been prepared in accordance with the Statement of Recommended Practice for Charities (SORP 2025), (Second Edition, effective January 2019), the Charities Act 2011 and applicable accounting standards (FRS102).

i. Accounting convention

The accounts are prepared under the historical cost convention.

ii. Donations receivable

Donations are credited to income when received.

iii. Tangible fixed assets and depreciation

Individual fixed assets costing £250 or more are capitalised at cost.

Depreciation is provided at rates calculated to write-off the cost less residual value of each asset over its expected useful life, as follows:

IT equipment – 33% straight line

2. Donated services

During the period the Charity received pro-bono legal services and a google grant to the value of £70,245 (2024: £127,921) which are shown within incoming resources under donated services in the statement of financial activities. An equivalent amount of expenditure of £70,245(2024: £127,921) is shown under resources expended within the statement of financial activities.

3. Payments to Trustees

During the year Amanda Cordell a Trustee, in her capacity as Chief Executive, received remuneration of £54,126 (2024: £48,464) . This employment was approved by the Charity Commission.

4. Governance

Trustees received no remuneration in their role as trustees.

24

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

5. Tangible Fixed Assets

6. Analysis of Staff Costs

7. Cost of Raising Funds

25

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

8. Resources Expended

9. Governance

26

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238

EOS Network – Eosinophilic Diseases Charity

Independent Examiner’s Report to EOS Network on the accounts for the year ending 31 March 2025 (Charity No: 1198883).

I report to the trustees on my examination of the accounts of the above charity (“the Trust”) for the year ending 31 March 2025 set out on pages 22-26.

Responsibilities and basis of report

As the charity’s trustees, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 (‘the act’).

I report in respect of my examination of the Trust’s accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed all applicable Directions by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner’s statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination which gives me cause to believe that in, any material respect:

• the accounting records were not kept in accordance with section 130 of the Charities Act; or

• the accounts did not accord with the accounting records; or

• the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a ‘true and fair view’ which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed: 01/10/2025 Date:

Relevant professional qualification(s) or body

Address:

Simon Robinson SAS Accounting Services Ltd The Colchester Centre Hawkins Road Colchester CO2 8JX

©2025 EOS Network

27

Doc ID: 64f41da33856efab7b289b0caaf74e97bbfc3238